iNTEGRATE fails to demonstrate significant cGVHD benefit for ibrutinib–prednisone regimen
Combining ibrutinib and prednisone for the treatment of new-onset chronic graft-versus-host disease after allogeneic haematopoietic cell transplantation does not improve patient response compared with prednisone alone, show phase 3 trial findings published in the Journal of Clinical Oncology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
